---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056260"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:13:40.022238+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexeo Q1 net loss $21.7M; cash $195.1M after $95M PIPE; pipeline milestones on track

## Summary
- Q1 2024 net loss $21.7M ($0.77/share) vs $18.7M ($11.58/share) in Q1 2023.
- Cash and equivalents $195.1M at March 31, 2024, after $95M PIPE; runway into 2027.
- LX2006 (FA cardiomyopathy) granted FDA Fast Track; interim readout mid-2024.
- LX2020 (PKP2-ACM) Phase 1/2 trial recruiting; Cohort 1 data update expected 2H 2024.
- LX1001 (APOE4 Alzheimer's) all-cohort interim data expected 2H 2024.

## SEC filing metadata
- accession: 0000950170-24-056260
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024056260/0000950170-24-056260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024056260/lxeo-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056260
- JSON: https://secwatch.observer/filing/0000950170-24-056260.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056260.txt

## Key facts
- Earnings Releases
  Lexeo Therapeutics, Inc. reported first quarter 2024 results: net income $21.7 million or $0.77 per share (basic and diluted), EPS $0.77 per share (basic and diluted).
  - Period: first quarter 2024
  - Net income: $21.7 million or $0.77 per share (basic and diluted)
  - EPS: $0.77 per share (basic and diluted)
  - Result: reported results
  source text: Net loss was $21.7 million or $0.77 per share (basic and diluted) for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000095017024056260/0000950170-24-056260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.